Navigation Links
Study identifies key molecules in multiple myeloma
Date:10/26/2010

COLUMBUS, Ohio New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood.

The findings might offer a new strategy for treating this disease and other blood cancers, according to researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) who led the study.

The silenced molecules are called miR-192, miR-194 and miR-215. All of them are microRNAs, a large class of molecules that are master regulators of many important cell processes.

The study, published in the Oct. 19 issue of Cancer Cell, suggests that re-activating these three molecules triggers expression of the P53 tumor suppressor gene. This, in turn, slows the growth and leads to the death of myeloma cells and could provide a new strategy for treating the disease.

"These findings provide a rationale for the further exploration of these microRNAs as a treatment for multiple myeloma, which has few therapeutic options," says principal investigator Dr. Carlo Croce, professor and chair of Molecular Virology, Immunology and Medical Genetics, and director of the Human Cancer Genetics program at the OSUCCC James.

Multiple myeloma is a disorder of white blood cells called plasma cells. More than 20,100 Americans are expected to develop the disease this year and some 10,600 are expected to die from it. Myeloma begins as a benign condition called monoclonal gammopathy of undetermined significance (MGUS). Individuals with MGUS can live for many years without treatment. Then, for unknown reasons, this benign condition can evolve into multiple myeloma.

Studies investigating the molecular causes of the disease have shown a relationship between P53 and another gene called MDM2. They have also shown that myeloma cells often have healthy (i.e., unmutated) P53 genes but very little P53 protein. P53 protein levels are restored, however, when MDM2 expression is blocked.

The study by Croce and his collaborators, which examines the role of microRNA in regulating the P53 pathway in myeloma cells, shows the following:

  • Expression of miR-192, miR-194 and miR-215 in multiple myeloma cells slows their growth and causes their death by activating the P53 gene.
  • Multiple myeloma cells from patients show high MDM2 expression compared with MGUS cells and normal plasma cells;
  • Expression of the three microRNAs dramatically lowers MDM2 expression levels and significantly increases P53 levels;
  • Treating myeloma cells with the three microRNAs plus an MDM2 inhibitor caused a two-fold rise in P53 expression and a three-fold drop in MDM2 expression;
  • Treating a myeloma mouse model with the three microRNAs caused a 50 percent reduction in tumor size compared with controls; treating the mice with the microRNAs plus an MDM2 inhibitor brought a five-fold reduction in tumor size.
  • Expression of the three microRNAs reduced the ability of myeloma cells to migrate and metastasize.

Overall, Croce says, "our results provide the basis for developing a microRNA-based therapy for multiple myeloma."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related biology news :

1. Landenberger Foundation awards grant to Scripps Florida scientist to study HIV
2. Penn study identifies molecular guardian of cells RNA
3. LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension
4. Offshore wind a mixed bag: University of Maryland study
5. Modeling study identifies characteristics of high elk-use areas in western Oregon, Washington
6. Universities receive grants to study climate change decisions
7. Center to study effects of plastics chemicals on childrens health
8. Study of tiny magnets may advance their use in microelectronics
9. BMC receives National Institutes of Health grant to study intrauterine cocaine and substance reslience
10. CRN responds to JAMA fish oil study
11. Singapore scientists first to perform genome-wide study of human stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... 16, 2016 The global wearable medical device market, in ... 2021 from USD 5.31 billion in 2016, at a CAGR of ... ... technological advancements in medical devices, launch of a growing number of ... connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... , Jan. 23, 2017   Instrument Business ... ( Minneapolis, MN ) the 2016 ... the most authoritative newsletter tracking developments in the ... "Bio-Techne consistently achieved outstanding technical, operational ... Samazan, Managing Editor of IBO. "In 2016, Bio-Techne ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
(Date:1/23/2017)... Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... the fostering of technology and monetization of intellectual property, ... lawsuits. Anthony Hayes , Chief Executive ... will continue to communicate with shareholders about the status ... due diligence on other patent assets that fit with ...
(Date:1/23/2017)... CALGARY , Jan. 23, 2017 /PRNewswire/ - Resverlogix ... preliminary results from the New Zealand ... impaired patients. The data showed remarkable results in reducing ... versus healthy control patients. It is believed that this ... direct connection of this type can be made between ...
Breaking Biology Technology: